Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC With High-grade Patterns and EGFR-sensitizing Mutations (APPOINT)

NCT04922138 is registered in ClinicalTrials.gov with Baohui Han as lead sponsor.

NCT NCT04922138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC With High-grade Patterns and EGFR-sensitizing Mutations (APPOINT)
Lead sponsor
Baohui Han
Phase
Phase 2
Overall status
Unknown status
Start date
January 14, 2022
Completion date
October 15, 2025
Enrollment
104 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer